Case #66: Part 3 – Amelanotic Malignant Uveal Melanoma – Page 15 of 17

References

• Russo A, Avitabile T, Reibaldi M, Bonfiglio V, Pignatelli F, Fallico M, Caltabiano R, Broggi G, Russo D, Varricchio S, et al. Iris Melanoma: Management and Prognosis. Applied Sciences. 2020; 10(24):8766.
• Shemesh, R., Bourla, N. & Vishnevskia-Dai, V. Characteristics of amelanotic iris lesions – a ten-year historical cohort. Graefes Arch Clin Exp Ophthalmol 262, 667–669 (2024).
• Shields, C. L., Kaliki, S., Hutchinson, A., Nickerson, S., Patel, J., Kancherla, S., Peshtani, A., Nakhoda, S., Kocher, K., Kolbus, E., Jacobs, E., Garoon, R., Walker, B., Rogers, B., & Shields, J. A. (2013). Iris Nevus Growth into Melanoma: Analysis of 1611 Consecutive Eyes. Ophthalmology, 120(4), 766–772.
• Krohn, J., Sundal, K.V. & Frøystein, T. Topography and clinical features of iris melanoma. BMC Ophthalmol 22, 6 (2022).